



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12P 7/04		A1	(11) International Publication Number: WO 91/09959 (43) International Publication Date: 11 July 1991 (11.07.91)
(21) International Application Number: PCT/JP90/01643			(74) Agents: AOYAMA, Tamotsu et al.; Twin 21 Mid Tower, 1-61, Shiromi 2-chome, Chuo-ku, Osaka-shi, Osaka 540 (JP).
(22) International Filing Date: 17 December 1990 (17.12.90)			(81) Designated States: CH, DE, GB, JP, US.
(30) Priority data: 1/339965 28 December 1989 (28.12.89) JP			Published <i>With international search report.</i>
(71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 3-6, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only) : SUGIYAMA, Yoshio [JP/JP]; 18-3, Iho 3-chome, Takasago-shi, Hyogo 676 (JP). MIYA, Hiroyuki [JP/JP]; 1-3, Satsukigaoka 5-chome, Ikeda-shi, Osaka 563 (JP). KAWADA, Mitsuru [JP/JP]; 25-3, Tsukaguchicho 4-chome, Amagasaki-shi, Hyogo 661 (JP).			
(54) Title: PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXY-2-METHYLBUTYRATES			
(57) Abstract			
A (2R, 3S)-3-hydroxy-2-methylbutyrate is efficiently and selectively produced by microbial asymmetric reduction of a 2-methyl-3-oxobutyrate with a bacterial strain or its processed material.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America

DESCRIPTION


PROCESS FOR PRODUCING OPTICALLY ACTIVE
3-HYDROXY-2-METHYLBUTYRATESTechnical Field

The present invention relates to a process for producing optically active 3-hydroxy-2-methylbutyrates which are useful starting materials for synthesis of good ferroelectric liquid crystal compounds and the like.

Namely, when 2-methyl-3-oxobutyrates of the formula:




wherein R is an ester forming group, is reduced according to an ordinary chemical method, for example, by using NaHB_4 , the following four stereomers are formed due to asymmetric carbon atoms at 2- and 3-positions:




(2R,3S)syn 2

(2)




(2S,3S)anti 3

(3)



(2S,3R)syn 4

(4)



(2R,3R)anti 5

(5)

wherein, R is as defined above and the symbol in the parentheses represents the absolute configuration of the asymmetric carbon atoms at 2- and 3-positions. Among these four stereomers, the present invention relates to a process for the selective production of the (2R, 3S)syn 2 isomers of the formula (2) by microbial asymmetric reduction. The isomer of the formula (2) are highly applicable to synthesis of good ferroelectric liquid crystal compounds as starting materials.

Background Art

Known processes for producing optically active 3-hydroxy-2-methylbutyrates from 2-methyl-3-oxobutyrates of the formula (1) by microbial asymmetric reduction include the processes using baker's yeast [A. Furuichi et al., Agric. Biol. Chem., 49, 9, 2563-2570 (1985); K. Nakamura et al., Tetrahedron Letters, 27, 3155 (1986); and K. Nakamura et al., Bull. Chem. Soc. Jpn., 62, 1179 (1989)] and the process using other yeast such as Candida albicans [H. Akita et al., Chem. Pharm. Bull., 31, 4376 (1983)]. However, these processes are not industrially advantageous processes in view of their low diastereomer selectivity and/or enantiomer selectivity. Further, microbial asymmetric reduction of 2-methyl-3-oxobutyrates with bacteria has not been known heretofore in the prior art.

Objects of the Invention

The main object of the present invention is to provide a process for selectively and efficiently producing optically active 3-hydroxy-2-methylbutyrates of the formula (2), which are useful starting materials for synthesis of good ferroelectric liquid crystal compounds, polyoxo-antibiotics, various naturally occurring physiologically active substances and the like, from the corresponding 3-oxo esters of the formula (1) by using microorganisms, particularly, bacteria.

This object as well as other objects and advantages of the present invention will become apparent to those skilled in the art from the following description.

Summary of the Invention

The present inventors have found that microbial asymmetric reduction of 2-methyl-3-oxobutyrates of the formula (1) can be efficiently conducted by using bacteria to form the desired optically active 3-hydroxy isomers.

Namely, according to the present invention, there is provided a process for producing a (2R,3S)-3-hydroxy-2-methylbutyrate of the formula (2) which comprises subjecting a 2-methyl-3-oxobutyrate of the formula (1) to asymmetric reduction with a bacterial strain or its processed material.

Disclosure of the Invention

In the process of the present invention, the ester forming group represented by R in the 2-methyl-3-oxobutyrate of the formula (1) used as the starting material is not specifically limited. For example, R may be lower alkyl, alkoxyalkyl or aralkyl. Examples of lower alkyl include alkyl having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl and the like. Examples of alkoxyalkyl include alkoxyalkyl having 3 to 6 carbon atoms such as methoxyethyl, ethoxyethyl, butoxyethyl and the like. Examples of aralkyl include phenyl(lower)alkyl such as benzyl, phenethyl, 1-methylbenzyl, 1-ethylbenzyl, 1-methylphenethyl, 2-methylphenethyl, 2-ethylphenethyl and the like. Among them, ethyl 2-methyl-3-oxobutyrate, isobutyl 2-methyl-3-oxobutyrate, butoxyethyl 2-methyl-3-oxobutyrate and benzyl 2-methyl-3-oxobutyrate are preferred. Particularly, ethyl 2-methyl-3-oxobutyrate is preferred from a practical point of view.

Although the formula (1) represents the keto tautomer, the compounds of the formula (1) can also be in the enol tautomer. The term "2-methyl-3-oxobutyrate" used herein includes each of these tautomers as well as a mixture thereof.

The bacteria used for the asymmetric reduction reaction of the present invention are not specifically

limited in so far as they have capability of asymmetric reduction. Examples thereof include bacteria belonging to genera Enterobacter, Erwinia, Escherichia, Klebsiella, Proteus, Salmonella, Serratia, Bacillus and Pediococcus. Any strain newly isolated from soil, food, animal, vegetable or the like can be used in so far as it is capable of producing the compound of the formula (2) from the compound of the formula (1) by asymmetric reduction. Further, the strain may be a mutant obtained by artificial mutagenesis by means of ultraviolet irradiation or treatment with a mutagenic agent, or other bacterial cells integrating an artificially isolated gene fragment necessary for expression of the corresponding reduction activity.

Specific examples of the bacterial strains used for asymmetric reduction of 2-methyl-3-oxobutyrates of the formula (1) include Enterobacter aerogenes IFO 13534, Enterobacter cloacae IFO 13535, Erwinia herbicola IFO 12686, Escherichia coli IFO 3549, Klebsiella pneumoniae IFO 3319, Klebsiella terrigena ATCC 33257 (IFO 14941, FERM BP-2710), Proteus vulgaris IFO 3045, Salmonella typhimurium IFO 14194, Serratia grimesii IFO 13537, Bacillus pumilus IFO 12090 and Pediococcus pentosaceus IFO 3892. Among these strains, Klebsiella terrigena ATCC 33257 is a known strain listed in Catalogue of BACTERIA & BACTERIOPHAGES, Vol. 17 (1989) published by American Type Culture Collection (ATCC), and is readily available from ATCC. This strain has also been

deposited at Institute for Fermentation, Osaka (IFO), Japan under the accession number of IFO 14941 since September 14, 1989. Further, it has been deposited at Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (FRI), Japan according to the Budapest Treaty under the accession number of FERM BP-2710 since December 26, 1989. The other strains are also known strains listed in LIST OF CULTURES, Vol. 8 (1988) published by IFO, and are readily available from IFO.

For conducting the process of the present invention, firstly, these bacterial strains are cultivated.

The cultivation of these strains can be conducted continuously or intermittently by means of normal stationary culture, shaking or agitating culture, submerged culture or solid culture. Culture media to be used may be those having normal compositions in which the bacteria used can be grown. As carbon sources, assimilable materials can be appropriately selected from carbohydrates, fatty acids, organic acids, alcohols and the like. They can be used alone or in combination thereof. Nitrogen sources include organic nitrogen sources such as peptone, yeast extract, meat extract, malt extract, corn steep liquor, soybean flour, urea and the like, as well as inorganic nitrogen sources such as ammonium sulfate, ammonium chloride, ammonium nitrate, ammonium phosphate and the like. They are

used alone or in combination thereof as occasion demands. In addition to these carbon and nitrogen sources, preferably, essential growth factors and growth promoters such as minerals, amino acids, vitamins and the like which are necessary for growth of the bacterial strains are added to the culture media.

An aqueous caustic alkali solution, an aqueous sodium carbonate solution or a calcium salt can be appropriately added to control pH during the cultivation. Further, it is advantageous to use an anti-foaming agent to control bubbling. Furthermore, it is also advantageous to aerate nitrogen gas or carbon dioxide gas to bring about anaerobic atmosphere depending upon the bacteria used.

Then, the cultivated strain or its processed material is brought into contact with the compound of the formula (1) to conduct the microbial asymmetric reduction.

As the bacterial strain, the resulting culture as it is or bacterial cells isolated by suitable means such as centrifugation, precipitation, agglutination, filtration through porous membrane, polymer membrane, ceramic membrane, etc. or the like can be used for the asymmetric reduction reaction.

The "processed material" used in the present invention includes masticated cells having capability of asymmetric reduction of the compounds of the formula (1) obtained by various physicochemical methods, for example,

sonication, French press, osmotic pressure, freeze-thawing, freeze-drying, alumina grinding and treatment with a lytic enzyme, a surfactant, an organic solvent and the like. The processed material also includes crude or purified enzymes contained in these cells and masticated cells obtained by purification thereof according to the methods described hereinafter. The enzymes can be solubilized by subjecting the above-obtained cells to physicochemical treatment, for example, freeze-thawing, grinding, sonication, dissolution of cell wall membrane, a surfactant or the like. The solubilized enzymes can be purified by further subjecting them to one or more conventional enzyme purification operations such as treatment with protamin, salting out, treatment with an organic solvent, isoelectric point precipitation, ion exchange chromatography, gel filtration, affinity chromatography, crystallization and the like. The enzymes thus obtained can be immobilized by inclusion in natural polymers such as alginate, carrageenan and the like, or synthetic polymers such as polyacrylamide, urethane resin and the like, or immobilized by binding to carriers such as activated charcoal, ceramic, dextran, agarose materials, porous glass, ion exchange resin and the like.

For conducting the asymmetric reduction reaction by bringing the compound of the formula (1) into contact with a culture of the bacterial strain or its processed material, the compound of the formula (1) is preferably used in an

concentration of 0.1 to 5% by weight, more preferably, 0.2 to 3% by weight. Further, it is desirable to add a carbon source assimilable by the bacterial strain (e.g., carbohydrate, fatty acid, organic acid, alcohol) as a hydrogen donor together with the compound of the formula (1). In order to promote the reaction, minerals and vitamins can also be added.

The reaction temperature is not limited to a specific range in so far as the asymmetric reduction can proceed. Preferably, the reaction temperature is in the range of 20 to 60°C, more preferably, 25 to 50°C. The pH range varies depending upon a particular bacterial strain used. When a bacterial strain belonging to the genus Pediococcus is used, pH 3 to 7 is preferred. When other bacterial strains are used, pH 5 to 9 is preferred. For efficient progress of the reduction reaction, preferably, the reaction mixture is suitably agitated. However, when a bacterial strain belonging to the genus Pediococcus is used, it is preferable to maintain anaerobic atmosphere. For this purpose, nitrogen gas or carbon dioxide gas can be aerated. On the other hand, when other bacterial strains are used, it is preferable to conduct the reaction under sufficient aerobic conditions.

The reaction is continued until the asymmetric reduction of the compound of the formula (1) is completed. Normally, it takes about 8 to 96 hours.

After the reaction, the optically active 3-hydroxy isomer thus formed can be readily recovered and collected by one or more known purification methods such as extraction, concentration and the like.

The compound of the formula (2) thus obtained by the process of the present invention can be converted into the corresponding 3-alkoxy-2-methylbutyrate by known alkylation of the hydroxy group followed by hydrolysis. Then, the 3-alkoxy-2-methylbutyrate is condensed with a side chain component containing no chiral center (or a side chain component containing a chiral center), whereby a good ferroelectric liquid crystal compound having excellent liquid crystal properties can be readily synthesized (e.g., EP-A-322862).

As described hereinabove, according to the process of the present invention, (2R,3S)-3-hydroxy-2-methylbutyrate which are useful starting materials for the production of good ferroelectric liquid crystal compounds and the like can be readily and efficiently produced.

The following examples and reference example further illustrate the present invention in detail but are not to be construed to limit the scope thereof.

Example 1

The following reduction reaction was conducted by using ethyl 2-methyl-3-oxobutyrate as the substrate and the ten strains shown in Table 1.

A bouillon slant culture of each strain was inoculated into a 200 ml Erlenmeyer flask containing a sterilized seed culture medium (20 ml) composed of Bacto tryptone 1%, Bacto yeast extract 0.5%, NaCl 0.5% and glucose 1%, and cultivated on a rotary shaker at 200 rpm at 28°C for 16 hours. The seed culture solution (each 0.3 ml portion) was transferred to 200 ml ribbed Erlenmeyer flasks containing a sterilized main culture medium (pH 7, 30 ml) composed of meat extract 1%, polypeptone 1%, NaCl 0.5%, CaCO₃ 4% and glucose 2% (separately sterilized) and cultivated with shaking at 200 rpm at 30°C. After 24 hours from the initiation of the cultivation, the substrate (120 mg) and glucose (1.2 g) were added to each flask and the cultivation was continued for additional 24 hours under the same conditions as those of the cultivation of the main culture. After completion of the reaction, the reaction mixture was extracted twice with the same volume (30 ml) of ethyl acetate and the combined ethyl acetate layer was washed with water, dehydrated and adjusted to a predetermined volume. A part of the extract was taken as a sample and the yield of the reduced product and syn/anti ratio were determined by gas chromatography as described hereinafter. On the other hand, the remaining extract was concentrated under reduced pressure. The resulting concentrate was dissolved in a small amount of ether and subjected to Kugel distillation to obtain a colorless oily

reduction product. The optical purity (enantiomeric excess) was determined by high performance liquid chromatography as described hereinafter.

The results are shown in Table 1. In each strain, diastereomer and enantiomer selectivity is higher than that obtained in known microbial asymmetric reduction using baker's yeast.

The analytical method and conditions used are as follows:

(1) Gas chromatography

Hitachi G-3000 gas chromatograph was used. Gas chromatography was conducted by using nonyl alcohol as an internal standard and chemically synthesized ethyl (2R, 3S)- and (2S, 3S)-3-hydroxy-2-methylbutyrate as authentic samples under the following conditions:

column: ULBON-20M (0.25 mm x 25 m)

column temperature: 110°C

carrier gas: He

detection: FID

(2) High performance liquid chromatography

Waters 600-E high performance liquid chromatograph was used. High performance liquid chromatography was conducted by using chemically synthesized four stereomers of ethyl 3-hydroxy-2-methylbutyrate as authentic samples under the following conditions:

column: Chiralcell OB (4.6 mm x 250 mm),

two columns

column temperature: 25°C

eluent: hexane : 2-propanol (99.5 : 0.5)

flow rate: 1.0 ml/min.

detection: UV 220 nm

Table 1

Strains	Reduction yield (%)	syn/anti ratio	Optical purity (% ee*)
<u>Enterobacter aerogenes</u> IFO 13534	84	98/2	syn 2 > 99
<u>Enterobacter cloacae</u> IFO 13535	95	99/1	syn 2 > 99
<u>Erwinia herbicola</u> IFO 12686	84	98/2	syn 2 > 99
<u>Escherichia coli</u> IFO 3549	95	99/1	syn 2 > 99
<u>Klebsiella pneumoniae</u> IFO 3319	99	98/2	syn 2 > 99
<u>Klebsiella terrigena</u> ATCC 33257 (IFO 14941, FERM BP-2710)	95	99/1	syn 2 > 99
<u>Proteus vulgaris</u> IFO 3045	99	96/4	syn 2 > 99
<u>Salmonella typhimurium</u> IFO 14194	83	96/4	syn 2 > 99
<u>Serratia grimesii</u> IFO 13537	85	96/4	syn 2 > 99
<u>Bacillus pumilus</u> IFO 12090	38	98/2	syn 2 > 99

*) ee: enantiomeric excess

Example 2


Pediococcus pentosaceus IFO 3892 strain grown by stab culture in commercially available GAM agar medium (manufactured by Nissui Seiyaku Kabushiki Kaisha, Japan) was inoculated in a 200 ml Erlenmeyer flask containing a sterilized seed culture medium (pH 6.6, 30 ml) composed of glucose 2%, polypeptone 1%, yeast extract 0.5%, meat extract 1%, Tween 80 0.1%, sodium acetate 0.3%, triammonium citrate 0.2%, $MgSO_4 \cdot 7H_2O$ 0.02% and $MnSO_4 \cdot 4-6H_2O$ 0.005% and cultivated by stationary culture at 30°C for 24 hours. This seed culture solution (each 1.5 ml portion) was transferred to 200 ml ribbed Erlenmeyer flasks containing a sterilized fermentation culture medium (pH 6.6, 30 ml) having the same composition as that of the seed culture medium except that $CaCO_3$ 1% was further added, and cultivated by stationary culture at 30°C. After 24 hours from the initiation of the cultivation, ethyl 2-methyl-3-oxobutyrate (60 mg) and glucose (1.2 g) were added to each flask. After replacing the gaseous phase by nitrogen gas, the reaction system was sealed and the reaction was conducted with shaking at 200 rpm at 30°C for 24 hours. After completion of the reaction, the reduction product was analyzed according to the same manner as that described in Example 1. As a result, the reduction yield was 30%, syn/anti ratio was 97 : 3 and optical purity of syn 2 isomer was more than 99% ee.

Example 3

Klebsiella pneumoniae IFO 3319 was cultivated according to the same manner as that described in Example 1. After 24 hours from the initiation of the cultivation of the main culture, each of five substrates shown in Table 2 (120 mg) and glucose 1.2 g were added to respective flasks and the reaction was conducted for 24 hours under the same conditions as those of the cultivation of the main culture. After completion of the reaction, each reaction mixture was extracted twice with the same volume (30 ml) of ethyl acetate. The combined ethyl acetate layer was washed with water, dehydrated and adjusted to a predetermined volume. A part of the extract was subjected to gas chromatography as described in Example 1. The resulting chromatogram was compared with that obtained by separately reducing the same substrate with baker's yeast to identify the peaks of the syn and anti isomers. Further, the syn/anti ratio was calculated by the area ratio of both peaks. On the other hand, the remaining extract was concentrated under reduced pressure. The concentrate was dissolved in a small amount of ether and subjected to Kugel distillation to obtain a colorless oily reduction product. The reduction product was dissolved in ethanol (8 ml) and the strong basic anion exchange resin, Amberlite IRA 402 (manufactured by Rohm and Haas Co., U.S.A., 0.4 ml) was added thereto. The mixture was stirred at room temperature for 48 hours to conduct the ester interchange reaction. The

resulting ethyl ester was isolated and determined by high performance liquid chromatography described in Example 1 to calculate the enantiomeric excess ratio. The optical purity was expressed by this ratio. The results are shown in Table 2.

Table 2

Substrate (R)	Reduction* yield (%)	syn/anti ratio	Optical purity (% ee)
isobutyl -CH ₂ CH(CH ₃) ₂	98	98/2	syn 2 > 99
neopentyl -CH ₂ C(CH ₃) ₃	94	98/2	syn 2 > 99
n-hexyl -C ₆ H ₁₃	45	95/5	syn 2 > 99
2-butoxyethyl -CH ₂ CH ₂ OC ₄ H ₉	95	97/3	syn 2 > 99
benzyl -CH ₂ - 	91	96/4	syn 2 > 99

*: Amount of substrate - Amount of remaining
used

$$\frac{\text{Amount of substrate used}}{\text{Amount of substrate used}} \times 100$$

Example 4

According to the same manner as that described in Example 1, a seed culture solution of Klebsiella pneumoniae IFO 3319 was prepared. The 20 ml portion of this culture solution was transferred to a 5 liter jar fermenter

containing a sterilized main culture medium (pH 7, 2 liters) composed of meat extract 1%, polypeptone 1%, NaCl 0.5% and an anti-foaming agent 0.05% and glucose 2% (separately sterilized) and cultivated at 30°C by submerged culture with stirring at 800 rpm and aeration rate of 0.6 liter/min. When the pH of the culture solution was dropped below 6.5 during the cultivation, an aqueous 15% (w/v) sodium hydroxide solution was added to maintain the pH at 6.5. After 18 hours from the initiation of the cultivation, ethyl 2-methyl-3-oxobutyrate (35 g) and an aqueous 40% (w/v) glucose solution (200 ml) were added, and the reaction was conducted for 24 hours under the same conditions as those of the cultivation of the main culture. The pH was adjusted according to the same manner as that described above. After completion of the reaction, the reaction mixture (2.18 liters) was extracted once with ethyl acetate (2 liters) and further twice with ethyl acetate (1 liter). The combined ethyl acetate layer was filtered to remove insoluble materials and the filtrate was washed with water and dehydrated. A part of the extract was taken as a sample and it was analyzed by gas chromatography as described in Example 1. As a result, the amount of remaining substrate was 0.5 g, the yield of the reduction product was 34.0 g (reduction yield: 97%) and syn/anti ratio was 99/1. On the other hand, the remaining extract was concentrated under reduced pressure to obtain a concentrate (35.1 g). The

concentrate was dissolved in a minimum amount of ether and subjected to Kugel distillation to obtain a colorless oily reduction product (33.5 g). The reduction product was separated and determined by high performance liquid chromatograph as described in Example 1. As a result, the amounts of syn 2, anti 3 and anti 5 formed were 33.0 g, 0.25 g and 0.10 g, respectively. No syn 4 was detected.

Example 5

According to the same manner as that described in Example 4, Klebsiella pneumoniae IFO 3319 was cultivated to obtain a main culture (about 2 liters).

i) Extraction of reductase

The main culture (1 liter) was centrifuged at 10,000 x g for 20 minutes to collect cells. The cells were washed once with 10 mM phosphate buffer solution (pH 6.0, about 200 ml, hereinafter merely referred to as buffer) containing 2-mercaptoethanol (5 mM) and phenylmethylsulfonyl fluoride (2 μ g/ml) by centrifugation to obtain washed cells (about 30 g, wet weight). All the washed cells were suspended in the buffer and the volume was adjusted to 150 ml with the buffer. Each 50 ml portion of the suspension was sonicated at output of 180 W for 20 minutes. The combined sonicated suspension was centrifuged at 35,500 x g for 20 minutes to obtain a supernatant (145 ml). When the protein concentration of this supernatant was determined by Protein Assay Kit (manufactured by Bio-Rad Inc., U.S.A.)

with bovine serum albumin as a standard, it was 33.5 mg/ml. Its activity for reducing ethyl 2-methyl-3-oxobutyrate determined by the method as described hereinafter was 0.30 U/ml.

The enzyme activity was determined as follows:

A reaction mixture having the total volume of 1 ml which was composed of phosphate buffer solution (pH 7.0, 40 μ mol), NADPH (0.2 μ mol), a substrate (ethyl 2-methyl-3-oxobutyrate, 2 μ mol) and an enzyme solution was maintained at 30°C, and the decrease in absorbance at 340 nm was continuously traced. The enzyme activity was expressed by "units (U)" and 1 U was defined as the amount of the enzyme which oxidized 1 μ mol of NADPH per 1 minute under the above conditions.

ii) Purification of enzyme

The above supernatant was diluted with the buffer so that the protein concentration became 10 mg/ml and solid ammonium sulfate was added little by little to obtain a 40% saturated solution. The precipitate thus formed was removed by centrifugation and solid ammonium sulfate was further added little by little to obtain a 80% saturated solution. The precipitate thus formed was collected by centrifugation and it was dissolved in the buffer. The volume was adjusted to 55 ml. The solution was dialyzed against the buffer (pH 8.0, 2 liters) at 4°C for 20 hours with replacing the buffer once with another fresh buffer in the course of the

dialysis. Insoluble materials formed during the dialysis were removed by centrifugation to obtain a clear supernatant.

The entire supernatant was applied to TSK-Gel DEAE-5PW column (20 x 150 mm) equilibrated with 10 mM phosphate buffer solution (pH 8.0) and the column was washed with the same buffer solution (200 ml). The enzyme was eluted with a gradient of sodium chloride in the same buffer solution linearly increasing from 0 to 0.15 M. The active fractions were collected and ammonium sulfate was added thereto to obtain a 90% saturated solution. The precipitate thus formed was recovered by centrifugation.

The precipitate was dissolved in a small amount of 50 mM phosphate buffer solution (pH 7.0) and the solution was adsorbed on a AF-Red Toyopearl column (25 x 50 mm) equilibrated with the same buffer solution. The enzyme was eluted with a gradient of sodium chloride in the same buffer solution linearly increasing from 0 to 1 M. The active fractions were collected and a precipitate was recovered by ammonium sulfate salting out according to the same manner as that described above.

The precipitate was dissolved in a minimum amount of 50 mM phosphate buffer solution (pH 7.0) containing 0.3 M sodium chloride. The solution was applied to TSK-Gel G 3000 SW column (20 x 300 mm) equilibrated with the same buffer solution. The column was eluted with the same buffer

solution. The protein concentration of the active fraction (13 ml) was 0.52 mg/ml and the enzyme activity was 1.17 U/ml. Accordingly, the recovery of the desired enzyme was about 35% and the purity was about 250 times based on the sonicated extract.

The uniformity of the purified enzyme was confirmed by polyacrylamide gel electrophoresis.

iii) Reduction of ethyl 2-methyl-3-oxobutyrate by purified enzyme

A reaction mixture having the total volume of 4 ml which was composed of phosphate buffer solution (pH 7.0, 400 μ mol), ethyl 2-methyl-3-oxobutyrate (200 μ mol), glucose (200 μ mol), NADPH (0.8 μ mol), glucose dehydrogenase (Bacillus sp., manufactured by Sigma, Co., U.S.A., 1 U) and the above purified enzyme (1 U) was reacted with shaking gently for 6 hours, while the temperature was maintained at 30°C. After completion of the reaction, the reaction mixture was extracted twice with the same volume (4 ml) of ethyl acetate. The combined ethyl acetate layer was dehydrated and the volume thereof was adjusted to the predetermined volume. The reduction product in a sample thereof was determined according to the same manner as that described in Example 1. As a result, the amounts of syn and anti isomers formed were 197 and 0.6 μ mol, respectively. All the syn isomers are syn 2 and no syn 4 isomer was detected. The turnover number of NADPH under these reaction

conditions was about 250.

Reference Example

Preparation of 4-[(2R, 3S)-3-methoxy-2-methylbutyryloxy]phenyl 4'-octyloxy-4-biphenylcarboxylate

i) Preparation of (2R, 3S)-3-methoxy-2-methylbutyric acid

Ethyl (2R, 3S)-3-hydroxy-2-methylbutyrate (8.20 g)

and methyl iodate (78.0 g) were dissolved in N,N-dimethylformamide (150 ml). To this solution was added sodium hydride (about 60% in oil, 2.46 g) little by little with ice cooling and the mixture was stirred for 1 hour with ice cooling. The reaction mixture was poured into ethyl acetate (300 ml) and the mixture was stirred for 10 minutes. Insoluble materials were filtered off and the filtrate was washed 3 times with water. The organic layer was dried, concentrated and distilled under reduced pressure (b.p. 80°C/30 mmHg) to obtain ethyl (2R, 3S)-3-methoxy-2-methylbutyrate (6.87 g).

This methyl ether (2.55 g) was dissolved in dioxane (50 ml) and conc. hydrochloric acid (36 %, 10 ml) and water (50 ml) were added to the solution. The solution was heated at 90°C for 5 hours. The reaction mixture was poured into water (100 ml) and the mixture was extracted 4 times with ethyl acetate. The combined extract was dehydrated, concentrated and distilled under reduced pressure (b.p. 105°C/1 mmHg) to obtain (2R, 3S)-3-methoxy-2-methylbutyric

acid (1.49 g).

$^1\text{H-NMR}$ and IR spectra of this compound are as follows:

$^1\text{H-NMR}$ (90 MHz, CDCl_3) δ : 1.15 (3H, s), 1.23 (3H, s), 2.5-2.8 (1H, m), 3.39 (3H, s), 3.47-3.74 (1H, m), 6.0 (1H, b)

IR ν cm^{-1} : 3450, 1710, 1100

ii) Esterification

(2R, 3S)-3-methoxy-2-methylbutyric acid prepared in the above i) (0.79 g), 4-hydroxyphenyl 4'-octyloxy-4-biphenylcarboxylate (2.5 g) and tributylamine (2.66 g) were dissolved in dehydrated tetrahydrofuran (40 ml) and 2-chloro-1-methylpyridinium iodide (1.84 g) was added thereto. The mixture was heated under reflux for 7 hours. Insoluble materials were filtered off and the filtrate was concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography [eluent: chloroform : n-hexane (4 : 1)] and recrystallized from ethanol to obtain the title compound (0.36 g).

$^1\text{H-NMR}$ and IR spectra of this compound are as follows:

$^1\text{H-NMR}$ (90 MHz, CDCl_3) δ : 0.90 (3H, t), 1.05-1.6 (16H, m), 1.8 (2H, b), 2.65-2.9 (1H, m), 3.40 (3H, s), 3.6-3.82 (1H, m), 4.01 (2H, t), 6.94-8.25 (12H, m)

IR ν cm^{-1} : 1760, 1730, 1610, 1510, 1100, 830

- 24 -

Elemental analysis for $C_{33}H_{40}O_6$,

Calcd: C, 74.41; H, 7.57

Found: C, 74.69; H, 7.52

CLAIM

1. A process for producing a (2R,3S)-3-hydroxy-2-methylbutyrate which comprises subjecting a 2-methyl-3-oxobutyrate to asymmetric reduction with a bacterial strain or its processed material.

2. A process according to claim 1, wherein the bacterial strain is selected from bacteria belonging to genera Enterobacter, Erwinia, Escherichia, Klebsiella, Proteus, Salmonella, Serratia, Bacillus and Pediococcus.

3. A process according to claim 2, wherein the bacterial strain is selected from the group consisting of Enterobacter aerogenes, Enterobacter cloacae, Erwinia herbicola, Escherichia coli, Klebsiella pneumoniae, Klebsiella terrigena, Proteus vulgaris, Salmonella typhimurium, Serratia grimessii, Bacillus pumilus and Pediococcus pentosaceus.

4. A process according to claim 3, wherein the bacterial strain is selected from the group consisting of Enterobacter aerogenes IFO 13534, Enterobacter cloacae IFO 13535, Erwinia herbicola IFO 12686, Escherichia coli IFO 3549, Klebsiella pneumoniae IFO 3319, Klebsiella terrigena ATCC 33257 (IFO 14941, FERM BP-2710), Proteus vulgaris IFO 3045, Salmonella typhimurium IFO 14194, Serratia grimessii IFO 13537, Bacillus pumilus IFO 12090 and Pediococcus pentosaceus IFO 3892.

5. A process according to claim 4, wherein the bacterial strain is Klebsiella pneumoniae IFO 3319.

6. A process according to claim 4, wherein the bacterial strain is Klebsiella terrigena ATCC 33257.

7. A process according to claim 1, wherein the processed material is masticated bacterial cells.

8. A process according to claim 1, wherein the processed material is a reductase contained in the bacterial strain.

9. A process according to claim 1, wherein the 2-methyl-3-oxobutyrate is used in a concentration of 0.1 to 5% by weight.

10. A process according to claim 1, wherein asymmetric reduction is conducted at 20 to 60°C.

11. A process according to claim 1, wherein asymmetric reduction is conducted at pH 3 to 9.

12. A process according to claim 1, wherein asymmetric reduction is conducted for 8 to 96 hours.

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP 90/01643

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC5: C 12 P 7/04

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
IPC5	C 12 P

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	WO, A1, 9009433 (SCHERING CORPORATION) 23 August 1990, see claims 1-12 --	1-12
A	Chemical Abstracts, volume 108, no. 9, 29 February 1988, (Columbus, Ohio, US), Buisson, Didier et al.: "New chiral building blocks by microbial asymmetric reduction: a direct access to functionalized 2R,3R- and 2S,3R-2-methyl-3-hydroxy butyrate synthons", see page 341, abstract 71630q, & Tetrahedron Lett. 1987, 28(42), 5033-5036 --	1-12
A	Chemical Abstracts, volume 100, no. 17, 23 April 1984, (Columbus, Ohio, US), Akita, Hiroyuki et al.: "The use of microorganisms in organic synthesis. I. Microbiological asymmetric reduction of 2-methyl-3-oxo-butyrate", see page 504, abstract 137316k, & Chem.Pharm.Bull. 1983, 31(12), 4376-4383 --	1-12

* Special categories of cited documents:¹⁰

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed


"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
20th March 1991	28.03.91
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer e.p.  MISS D. S. KOWALCZYK

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	
A	<p>Chemical Abstracts, volume 103, no. 25, 23 December 1985, (Columbus, Ohio, US), Furuichi, Akiya et al.: "Enzymes producing two chiral centers. Part I. Purification and properties of an asymmetric reduction enzyme of 2-methyl-3-oxobutyrate in bakers' yeast.", see page 401, abstract 209519r, & Agric.Biol.Chem. 1985, 49(9), 2563-2570</p> <p>---</p> <p>-----</p>	1-12

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/JP 90/01643

SA 42646

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 28/02/91
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A1- 9009433	23/08/90	AU-D-	5044390	05/09/90